Systemic Therapy for Metastatic Prostate Cancer with Low PSA
For metastatic hormone-sensitive prostate cancer (mHSPC) with low PSA, initiate ADT combined with a novel hormonal agent (abiraterone + prednisone, apalutamide, or enzalutamide), or consider triplet therapy with ADT + docetaxel + novel hormonal agent (abiraterone or darolutamide) for fit patients, particularly those with high-volume disease features. 1
Understanding Low PSA Metastatic Disease
Low PSA metastatic prostate cancer represents a distinct clinical entity with important prognostic and therapeutic implications:
Aggressive histology predominates: These tumors typically demonstrate poorly differentiated adenocarcinoma, small cell features, or neuroendocrine differentiation, with chromogranin-A and neuron-specific enolase positivity common on immunohistochemistry. 2, 3
Atypical metastatic patterns: Expect visceral metastases (liver 55%, lung 33%), lytic or mixed bone lesions (rather than purely blastic), and lymph node involvement more frequently than typical PSA-elevated disease. 2
Alternative tumor markers: Monitor CEA, CA19-9, CA15-3, CA125, and neuron-specific enolase, as these are often elevated when PSA remains low and can guide disease monitoring. 2, 3
First-Line Treatment Algorithm for mHSPC
For Fit Patients with De Novo Metastatic Disease:
Triplet therapy is preferred, especially with multiple bone metastases (>3) or visceral involvement:
- ADT + docetaxel + abiraterone + prednisone (ESMO-MCBS score: 4, though not EMA/FDA approved as triplet) 1
- ADT + docetaxel + darolutamide (ESMO-MCBS score: 4) 1
Alternative doublet therapy (novel hormonal agent + ADT):
- ADT + abiraterone + prednisone (ESMO-MCBS score: 4) 1
- ADT + apalutamide (ESMO-MCBS score: 4) 1
- ADT + enzalutamide (ESMO-MCBS score: 4) 1
Special Consideration for Low PSA with High-Grade Disease:
For patients with Gleason 8-10 and PSA <4 ng/mL who are in good health (performance status 0), adding docetaxel to standard therapy significantly reduces prostate cancer-specific mortality (sHR 0.30,95% CI 0.11-0.86). 4
For Vulnerable Patients:
ADT alone should only be used in patients who cannot tolerate treatment intensification due to comorbidities or poor performance status. 1
Progression to Castration-Resistant Disease (mCRPC)
After Progression on Novel Hormonal Agent + ADT ± Docetaxel:
Sequence therapy based on prior treatments and molecular features:
If BRCA1/2 Alterations Present:
- Olaparib after progression on androgen receptor axis inhibitors (with or without prior taxane), showing OS benefit (HR 0.69, medians 19.1 vs 14.7 months; ESMO-MCBS score: 3) 1
If PSMA-Expressing Disease on PET Imaging:
- 177Lu-PSMA-617 for patients who received both a novel androgen receptor axis inhibitor and docetaxel, demonstrating significant OS improvement (HR 0.62, medians 15.3 vs 11.3 months; ESMO-MCBS score: 4) 1
- Requires PSMA expression on PET imaging (Ga-68 PSMA-11, F-18 piflufolastat, or F-18 flotufolastat) and absence of PSMA non-expressing lesions 1
Alternative Chemotherapy:
- Cabazitaxel for fit patients after docetaxel and novel hormonal agent progression (ESMO-MCBS score: 3) 1
Critical Pitfalls in Low PSA Disease
Do not rely solely on PSA for disease monitoring: The biological variability in these tumors, including subclones producing minimal PSA, necessitates monitoring alternative tumor markers (CEA, CA19-9, CA15-3, CA125) and clinical/radiographic assessment. 2, 3, 5
Expect platinum sensitivity: Low PSA metastatic disease with neuroendocrine features demonstrates higher response rates to cisplatin-based chemotherapy (66.6% objective response rate), though this is typically reserved for true small cell or neuroendocrine variants. 2
Maintain high clinical suspicion: Unexplained skeletal lesions (particularly lytic), visceral metastases, or rapid clinical deterioration warrant aggressive diagnostic workup including biopsy, even with normal or minimally elevated PSA. 5
Monitor blood counts, renal, and hepatic function before each cycle of systemic therapy, particularly with 177Lu-PSMA-617, which requires radioprotection precautions per local regulations. 1